Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Up to fifty (50) children and adolescents with type 1 diabetes (T1D) aged 4 to ˂18 years at
time of enrolment will be selected for inclusion in the study. The target is to obtain
treatment response and user-experience data following use of Nasal Glucagon (LY900018) in
treating episodes of hypoglycemia.